| Innovation Title | Categories | Lead Inventor | |
|---|---|---|---|
|
Tool to Rapidly Discover Biased Agonists of Delta Opioid Receptor and Other G Protein-Coupled Receptors
2021-VANR-69275 |
van Rijn, Richard M | ||
|
Novel Adenylyl Cyclase 1 Inhibitors for Treatment of Chronic Pain
2020-FLAH-68825 |
Flaherty, Daniel P | ||
|
Non-Opioid for Treating Chronic Pain and Opioid Dependence
2017-WATT-67867 |
Watts, Val J | ||
|
Novel Adenylyl Cyclase 1 Inhibitors for Chronic Pain and Opioid Dependence
2017-WATT-67991 |
Watts, Val J | ||
|
Simultaneous Treatment of Alcohol Use and Psychiatric Disorders
2017-VANR-67884 |
van Rijn, Richard M | ||
|
Dr. Richard M. van Rijn is an Associate Professor of Medicinal Chemistry and Molecular Pharmacology at Purdue University. He earned a B.S. and M.S. in Biopharmaceutical Sciences at Leiden University, Leiden, Netherlands, and a Ph.D. in Molecular Pharmacology from Vrije Universiteit Amsterdam. Dr. van Rijn's research focuses on understanding the development of drug dependence, long-term effects of chronic drug abuse on neuropharmacology, and the effect that neurological disorders have on the progression of drug dependence. His goal is to develop new pharmaceuticals that may assist in treating drug dependence. Current research projects include investigation into the role of beta-arrestin dependent signaling in depression and anxiety disorders, opioid and alcohol use disorders, chronic pain disorders, locomotor dysfunction, seizures, and developing novel opioid therapeutic leads through natural products and de novo synthesis. For additional information, visit Dr. Van Rijn's Purdue website: http://www.mcmp.purdue.edu/faculty/?uid=rvanrijn or his Van Rijn Lab website: http://www.vanrijnlab.com/ |
|
|
